SLN
HealthcareSilence Therapeutics plc
$5.93
$-0.22 (-3.58%)
Jan 5, 2026
Price History (1Y)
Analysis
Silence Therapeutics plc is a biotechnology company operating in the healthcare sector. With a market capitalization of $280.10 million, it is a relatively small player in its industry, employing 116 people. Financially, Silence Therapeutics plc reports significant losses, with net income standing at -$64,540,000 and EBITDA at -$69,405,000 over the trailing twelve months. Its gross margin is 91.3%, but operating and profit margins are deeply negative, at -14881.1% and -249.9%, respectively. The company's return on equity and assets stand at -64.3% and -23.4%, indicating significant losses relative to its shareholder base and total assets. Silence Therapeutics plc has a debt-to-equity ratio of 0.25, supported by cash reserves of $102.19 million. Valuation metrics for Silence Therapeutics plc are mixed, with a forward P/E ratio of -6.59 and an EV/EBITDA ratio of -11.09, suggesting significant undervaluation if earnings were to recover. However, the Price to Book ratio stands at 3.78, indicating some premium relative to its tangible assets. Revenue growth has been negative over the past year, at -89.4%, though dividend payments are not made by the company.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Silence Therapeutics plc
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Visit website →Key Statistics
- Market Cap
- $280.10M
- P/E Ratio
- N/A
- 52-Week High
- $7.78
- 52-Week Low
- $1.97
- Avg Volume
- 255.29K
- Beta
- 1.31
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United Kingdom
- Employees
- 116